Program By Day

7:00 AM-7:55 AM Poster Session C: Renal Cell Cancer
With Complimentary Continental Breakfast Beginning at 6:30 AM
7:00 AM-7:55 AM Trials in Progress Poster Session C: Renal Cell Cancer
With Complimentary Continental Breakfast Beginning at 6:30 AM
7:00 AM-7:45 AM Best of Journals: Renal Cell Cancer

Umberto Capitanio
Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute
Urology

Cora N. Sternberg, MD, FACP
San Camillo Forlanini Hospital
Medical Oncology

TBD
Radiology

Panel Question and Answer
7:00 AM-7:45 AM Best of Journals: Urothelial Carcinoma

Sam Chang, MD
Vanderbilt University Medical Center
Urology

Andrea B. Apolo, MD
National Cancer Institute
Medical Oncology

Robert A. Huddart, MBBS, MRCP, FRCR, PhD
Institute of Cancer Research and Royal Marsden Hospital
Translational Science

Panel Question and Answer
7:55 AM-8:45 AM Welcome and General Session 7: Management of Adrenocortical Carcinoma and Pheochromocytoma

Jeffrey M. Holzbeierlein, MD, FACS—Chair
University of Kansas Health System

N. Reed Dunnick, MD—Chair
University of Michigan

TBD
Welcome

TBD
Endocrinologic Issues in Adrenocortical Carcinoma and Pheochromocytoma

David I. Quinn, MBBS, PhD, FACP
University of Southern California Norris Comprehensive Cancer Center
Management of Metastatic Disease for Adrenocortical Carcinoma and Pheochromocytoma

Jonathan Coleman, MD
Memorial Sloan-Kettering Cancer Center
Surgical Management of Adrenocortical Carcinoma and Adrenal Tumors

Panel Question and Answer
8:45 AM-9:30 AM Renal Cell Cancer: Keynote Lectures

Robert J. Motzer, MD
Memorial Sloan-Kettering Cancer Center
Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: Past, Present, and Future

Bernard J. Escudier, MD
Gustave Roussy Cancer Campus
The Future of Immuno-Oncology in Renal Cell Carcinoma

Panel Discussion
Panel Question and Answer
9:30 AM-10:00 AM Break
10:00 AM-11:30 AM General Session 8: Comprehensive Characterization and Management of the Incidental Renal Mass

Stephen A. Boorjian, MD—Chair
Mayo Clinic

Edwin J. Abel, MD—Chair
University of Wisconsin School of Medicine and Public Health

Stuart G. Silverman, MD
Brigham and Women's Hospital
Optimal Imaging for the Indeterminate Renal Mass on CT: How to Determine What Is Indeterminate

Ithaar Derweesh, MD
University of California, San Diego
The Importance of Tumor Heterogeneity for the Interpretation of Renal Mass Biopsy

Antonio Finelli, MD
University of Toronto
Optimal Patient Selection for Active Surveillance or Ablation in Small Renal Tumors

TBD
How to Interpret the Data on Renal Function Preservation After Nephrectomy: Has the EORTC Trial Put the Issue to Rest?

Steven C. Campbell, MD, PhD
Cleveland Clinic
Oncologic and Functional Follow-up After Renal Mass Treatment

Panel Question and Answer
11:30 AM-1:00 PM Poster Session C: Renal Cell Cancer
With Complimentary Boxed Lunch
11:30 AM-1:00 PM Trials in Progress Poster Session C: Renal Cell Cancer
With Complimentary Boxed Lunch
11:45 AM-12:45 PM Rapid-Fire Abstract Session: Renal Cell Cancer
12:00 PM-12:45 PM Poster Walks
1:00 PM-2:30 PM Oral Abstract Session C: Renal Cell Cancer
2:30 PM-2:45 PM Break
2:45 PM-4:15 PM General Session 9: Multidisciplinary Care of the Patient With Advanced Renal Cell Carcinoma: How to Utilize Current Clinical Trial Data and What to Do in the Absence of Level I Evidence

Daniel Yick Chin Heng, MD, MPH—Chair
University of Calgary

TBD
Value of Lymph Node Dissection in the M0 and M1 Patient

Naomi B. Haas, MD
University of Pennsylvania
Status of Adjuvant Therapy in Renal Cell Carcinoma in 2018: What Have the Completed Trials Told Us and What Is Being Tested?

Axel Bex, MD, PhD
The Netherlands Cancer Institute
Timing and Patient Selection for Cytoreductive Nephrectomy

TBD
Optimal Sequencing of First and Second Line Systemic Therapy in Metastatic Clear Cell Renal Cell Carcinoma

TBD
Current Role of Metastasectomy in Renal Cell Carcinoma

Panel Question and Answer